1 Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating 2 Monooxygenase influence GLP-1 levels and response to GLP-1 3 Receptor Agonists

- Mahesh M Umapathysivam^{*1,2,3,4}, Elisa Araldi^{*5,6,7}, Benoit Hastoy¹, Adem Y Dawed^{8†}, Hasan 6 Manesh M Umapathysivam ^{ALS1}, Elisa Araidi ^{56,4}, Benoît Hastoy⁷, Adem Y Dawed⁵¹, Hasan Vatandaslar⁵, Shahana Sengupta¹, Adrian Kaufmann⁵, Søren Thomsen¹, Bolette Hartmann⁹, Anna E Jonsson¹⁰, Hasan Kabakci⁵, Swaraj Thaman¹¹, Niels Grarup¹⁰, Christian T Have¹⁰, Kristine Færch^{9,10}, Anette P Gjesing¹⁰, Sameena Nawaz¹, Jane Cheeseman^{1,12}, Matthew J Neville^{1,12}, Oluf Pedersen^{13††}, Mark Walker¹⁴, Christopher Jennison¹⁵, Andrew T Hattersley¹⁶, Torben Hansen¹³, Fredrik Karpe^{1,12}, Jens J Holst^{9,13}, Angus G Jones¹⁶, Michael Ristow⁵, Mark I McCarthy^{1,12,17,19#} 7 8 9 10 11 12 13 14 1. Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, UK 15 2. Department of Endocrinology, Queen Elizabeth Hospital, SA Health, Australia 16 3. Southern Adelaide and Diabetes and Endocrinology Service, Bedford Park, Australia 17 4. NHRMC Centre of Clinical research Excellence in Nutritional Physiology, Interventions and outcomes 18 University of Adelaide, South Australia, Australia 19 5. Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zürich, Switzerland 20 6. Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zürich, 21 Switzerland. 22 7. Department of Cardiology and Center for Thrombosis and Hemostasis, University Medical Center of the 23 Johannes Gutenberg University Mainz, Mainz, Germany 24 8. Division of Population Health & Genomics, School of Medicine, University of Dundee, UK 25 9. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University Copenhagen, 26 Denmark 27 10. Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark 28 11. Division of Endocrinology, Department of Pediatrics, Stanford School of Medicine, Stanford, USA 29 12. National Institute of Health Research, Oxford Biomedical Research Centre, Churchill Hospital, 30 Headington, Oxford, UK 31 13. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark 32 14. Translational and Clinical Research Institute, Newcastle University, UK 33 15. Department of Mathematics, University of Bath, UK 34 16. University of Exeter College of Medicine & Health, Exeter, UK 35 17. Wellcome Trust Centre for Human Genetics, University of Oxford, UK 36 18. Medical Faculty, University of Zürich, Zürich, Switzerland 37 19. Stanford Diabetes Research Centre, Stanford, USA 38 39 *These authors contributed equally to the study 40 #These authors jointly supervised the study 41 [†]Current affiliation: Department of Genetics, Novo Nordisk Research Centre Oxford, Oxford, UK 42 ^{††}Center for Clinical Metabolic Research, Gentofte University Hospital, Copenhagen, Denmark 43 Current address: Genentech, 1 DNA Way, South San Francisco, CA 94080 44 45 **Corresponding Author:** 46 Anna L. Gloyn DPhil Department of Pediatrics, Division of Endocrinology & Diabetes, MC 5660, Stanford 47 48 School of Medicine, Centre for Academic Medicine, 453 Quarry Road, Palo Alto, CA 49 94304
- 50 agloyn@stanford.edu

51 ABSTRACT

52 Patients with type 2 diabetes vary in their response to currently available therapeutic 53 agents (including GLP-1 receptor agonists) leading to suboptimal glycemic control 54 and increased risk of complications. We show that human carriers of hypomorphic 55 T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating 56 monooxygenase (PAM), as well as Pam-knockout mice, display increased resistance 57 to GLP-1 in vivo. Pam inactivation in mice leads to reduced gastric GLP-1R 58 expression and faster gastric emptying: this persists during GLP-1R agonist 59 treatment and is rescued when GLP-1R activity is antagonized, indicating resistance 60 to GLP-1's gastric slowing properties. Meta-analysis of human data from studies 61 examining GLP-1R agonist response (including RCTs) reveals a relative loss of 44% 62 and 20% of glucose lowering (measured by glycated hemoglobin) in individuals with hypomorphic PAM alleles p.S539W and p.D536G treated with GLP-1R agonist. 63 64 Genetic variation in *PAM* has effects on incretin signaling that alters response to 65 medication used commonly for treatment of T2D.

66

- 67 (Funded by the Wellcome, Medical Research Council, European Union, NIHR Oxford Biomedical
- 68 Research Centre, United Kingdom, Registered on ClinicalTrials.gov, NCT02723110.)
- 69
- 70

71

73 Summary Paragraph

74 Type 2 diabetes (T2D) is a leading cause of morbidity and mortality globally¹. 75 Current management of T2D patients focuses on lowering glycemic exposure and reducing complications with lifestyle and pharmacological interventions². Despite the 76 77 availability of multiple medications to lower glycated hemoglobin (HbA1c), only 53% of individuals with T2D reach the glycemic target (HbA1c <7%)^{3, 4}. There is potential 78 79 to improve medication selection through "precision medicine" where patient specific 80 factors (e.g. genetic markers) are used to indicate whether a patient is more or less 81 likely to respond to a medication. Here we show that human carriers of hypomorphic 82 T2D-risk alleles in the gene encoding peptidyl-glycine alpha-amidating 83 monooxygenase (PAM), as well as Pam-knockout mice, have reduced PAM enzyme 84 activity, display increased resistance to glucagon like peptide 1 (GLP-1) in vivo and 85 have reduced response to the GLP-1 receptor agonist. Meta-analysis of human data 86 from studies examining GLP-1 receptor agonist response (including RCTs) reveals a 87 relative loss of 44% and 20% of glucose lowering (measured by glycated 88 hemoglobin) in individuals with hypomorphic PAM alleles p.S539W and p.D536G 89 treated with GLP-1 receptor agonist. Genetic variation in PAM has effects on incretin 90 signaling that alters response to medication used commonly for treatment of T2D.

91 Main text

Two independent loss of function coding alleles in *PAM* (p.S539W, rs78408340, minor allele frequency (MAF) ~1%, OR: 1.47 and p.D563G, rs35658696, MAF ~5%, OR: 1.23) increase T2D risk and reduce beta cell function ⁵⁻⁷. The *PAM* gene encodes the PAM protein, which is the only enzyme capable of amidating the Cterminal glycine residue of certain peptides to an amide group, a post-translational mechanism necessary for full biological activity and stability of many hormones^{8, 9}.

medRxiv preprint doi: https://doi.org/10.1101/2023.04.07.23288197; this version posted April 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

98 Several hormones known to regulate blood glucose concentration are amidated (e.g. gastrin, cholecystokinin and glucagon-like peptide 1(GLP-1)) 9-12. Aside from 99 100 amidation, PAM also has several non-catalytic functions, including a role in intracellular protein trafficking^{7, 13}. We have shown *in vitro* that PAM deficiency in 101 102 human pancreatic beta cells causes reduced insulin content and altered dynamics of 103 insulin secretion⁷. These experiments informed on the impact of PAM inactivation on 104 beta-cell function in cell autonomous situations but were not able to assess whether 105 PAM deficiency contributes to elevated diabetes risk by regulating other hormones 106 affecting insulin secretion, gastric emptying or other metabolic pathways affected in 107 diabetes. PAM knockdown in beta-cells altered the kinetics of exocytosis and the 108 immediately available pool of insulin granules, this will reduce the effectiveness of 109 GLP-1 in stimulating insulin secretion⁷. As a result, it is likely that, altered GLP-1 110 response is a contributing factor to the diabetes risk phenotype observed in carriers 111 of p.D563G and p.S539W⁷. GLP-1 is itself amidated by PAM and interacts with several other amidated peptides which regulate its secretion via multiple 112 mechanisms¹⁴⁻¹⁶. 113

Altered GLP-1 plasma levels or GLP-1 sensitivity in carriers of *PAM* T2D risk alleles could have implications for the efficacy of two commonly prescribed medications for T2D: GLP-1R agonists (GLP-1RA) and dipeptidyl-peptidase 4 inhibitors (DPP-4i). Given that \approx 10% of individuals carry a loss of function allele in the *PAM* gene, demonstration of GLP-1 deficit or resistance in carriers of PAM T2D risk alleles would impact the medication choice for many individuals with T2D ⁵⁻⁷.

120 Amidation activity is reduced in carriers of PAM loss of function alleles and

121 *Pam* knockout in mice.

122 First we confirmed that carriers of the PAM loss of function (LoF) alleles p.D536G 123 (MAF~5%, presumed partial LoF) and p.S539W (MAF 1%, presumed complete LoF) 124 have reduced in vivo PAM function by measurement of PAM amidation activity in serum from non-diabetic white individuals from the Oxford Biobank¹⁷. PAM activity 125 126 was measured in 24 heterozygous carriers of the p.S539W allele, 27 heterozygous 127 and 21 homozygous carriers of the p.D563G allele and age, sex and BMI matched 128 non-carriers. We observed a 52% reduction in amidation activity in heterozygous 129 carriers of the p.S539W allele compared to non-carriers (188±13 vs 392±13 $pmol/ml/hr p=9.3x10^{-15}$, (**Fig. 1a**). Similarly, we observed a 20% (300±11 vs 370±14) 130 131 pmol/ml/hr, p=0.0008) and 38% (272±10 vs 472±17 pmol/ml/hr, p=1.4 x 10⁻⁹) 132 decrease in PAM serum activity in heterozygous and homozygous carriers of 133 p.D536G compared to non-carriers, respectively (Fig. 1b).

134 Concomitantly, to understand how loss of PAM affects systemic processes 135 influencing diabetes onset, we created an inducible Pam whole-body knockout mouse model (UBC-Er2-Cre Pam^{1/fl}, Supplementary Fig. 1a). Pam^{1/fl} mice were 136 137 crossed with mice expressing a tamoxifen-inducible Cre-Ert2 fusion gene under the control of the human ubiquitin C (UBC) promoter ¹⁸, and UBC-Er2-Cre Pam^{f1/f1} and 138 littermates of genotype Pam^{fl/fl} were treated with tamoxifen at 4 weeks of age to 139 140 generate Pam whole-body knockouts (hereby referred to as UBC-Cre Pam^{fl/fl}) or control tamoxifen-treated Pam wild type littermates (or Pam^{fl/fl}). Effective Pam^{fl/fl} 141 allele recombination and lack of Pam expression in UBC-Cre Pam^{fl/fl} mice was 142 143 assessed by gene expression and *Pam* ablation in different tissues (Supplementary 144 Fig. 1b-d). Supporting the observations in individuals carrying loss of function alleles

(Fig. 1a, b), PAM amidation activity was absent in the whole-body knockout mice
(Fig. 1c, Supplementary Fig. 1e).

147 Postprandial GLP-1 concentration is increased in *PAM* LoF allele carriers and

148 *Pam* knockout mice

149 Having demonstrated the functional impact of p.D536G and p.S539W on PAM 150 amidation activity in vivo we assessed the impact of this on postprandial amidated. 151 unamidated and total (sum of amidated and unamidated) plasma GLP-1 152 concentration in humans. We retrospectively examined amidated GLP-1 levels in two 153 Danish Cohorts (AdditionPRO and Family studies – **Supplementary Table 1**)^{20,21}. In 154 the Family Study, amidated plasma GLP-1 levels (7-36 amide and 9-36 amide) were 155 measured at 10 timepoints following an OGTT. We compared GLP-1 profiles and 156 the AUC₁₂₀ in 26 Danish carriers of the p.D536G allele and 56 matched non-carriers (Fig. 2a) ^{19, 20}. The peak amidated GLP-1 concentration was higher in the carriers of 157 158 the p.D536G allele (17.7±1.3 vs 23.9±3.4 pmol/L, p=0.04), as was the overall postprandial exposure, measured by GLP-1 AUC₁₂₀ (2498±168 vs 3251±303 pmol.L⁻ 159 160 ¹.min, p=0.02). Only 3 heterozygous carriers of the p.S539W allele were identified in 161 the Family study participants. This study was underpowered to detect a difference in 162 carriers of p.S539W and did not demonstrate a significant difference (1340±220 vs 1895±62 pmol.L⁻¹.min., p=0.13) (**Fig. 2b**). 163

The observation of increased GLP-1 concentration in carriers of PAM diabetes risk alleles is discordant with prior studies which demonstrated reduced GLP-1 concentrations in individual with pre-diabetes and diabetes compared with nondiabetic individuals²¹⁻²³. We sought to prospectively re-confirm the impact of PAM deficiency on postprandial GLP-1 levels and assess the consequence of altered GLP-1 levels on the incretin response using an isoglycaemic clamp, the gold

medRxiv preprint doi: https://doi.org/10.1101/2023.04.07.23288197; this version posted April 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

standard measure of the incretin response ²⁴. We performed a recruit-by-genotype 170 171 study in 19 white normoglycaemic carriers of the presumed complete LoF allele 172 p.S539W from the Oxford Biobank and on 19 age, sex and BMI matched non-173 carriers. We measured amidated and glycine extended GLP-1 concentration (both of 174 which are biologically active) and calculated the total GLP-1 concentration at 10 time 175 points following a 75g oral glucose load. The total (sum of amidated and 176 unamidated) GLP-1 profiles were significantly higher in carriers compared to non-177 carriers (p=0.024) (**Fig. 2b-c**). The mean AUC₂₄₀ was higher in carriers compared to 178 non-carriers (Total GLP-1: 7692 ± 304 vs 6887 ± 230 min.pmol/L p=0.04). 179 Importantly, there were no significant differences in insulin or glucose profiles 180 between genotypes or ratio of amidated to non-amidated GLP-1 at any time point 181 (Table 1).

182 Consistent with our observation in human carriers of PAM LoF alleles, in UBC-Cre Pam^{fl/fl} knockout mice, total GLP-1 was not different in the fasted state but 183 184 significantly higher compared to control after oral glucose load (Supplementary Fig. 3d). Importantly, content of GLP-1 in duodenum and jejunum of UBC-Cre Pam^{fl/fl} 185 mice lacking Pam was identical to that of control Pam^{fl/fl} littermates (Supplementary 186 187 Fig. 3a-b), and DPP4 activity was similarly unchanged between the two groups 188 (Supplementary Fig. 3c). A similar increase in GLP-1 was also obtained in refed UBC-Cre Pam^{fl/fl} mice compared to Pam^{fl/fl} (Fig. 2d). These data indicate that the 189 190 increase in GLP-1 after glucose challenge or feeding in mice lacking Pam is not due 191 to differences in GLP-1 production or DPP4 activity, but rather on altered GLP-1 192 secretion.

194 Carriers of *PAM* LoF alleles and whole-body *Pam* knockout mice demonstrate

195 GLP-1 resistance

196 Having demonstrated elevated GLP-1 concentration in carriers of PAM LoF alleles 197 we assessed the functional impact on postprandial glucose homeostasis by 198 measuring the incretin effect. The incretin effect refers to the disposal of glucose 199 related to the secretion of the gut released peptides, GLP-1 and glucose dependent insulinotropic polypeptide (GIP) in response to nutrient ingestion²⁵. We quantified the 200 201 incretin effect with the gold standard isoglycemic clamp in the same 19 p.S539W carriers and non-carriers from the Oxford Biobank²⁵. Despite higher postprandial 202 203 GLP-1 concentrations there was no difference in the incretin response in carriers 204 compared to non-carriers (47.5% ± 14.4 vs 50.7% ± 11.3, p=0.50) (Fig. 3a). To 205 quantify GLP-1 action, we compared the ratio of incretin effect to the peak total 206 (amidated and unamidated) GLP-1. We found a 18% reduction in GLP-1 sensitivity 207 as measured by GLP_{peak}:incretin effect ratio in carriers of p.S539W compared to non-208 carriers (0.69±0.05 vs 0.83±0.04, p=0.04) (Fig. 3b). To exclude contribution of GIP 209 (the major contributor to the incretin effect in health) to the observed phenotype, GIP 210 AUC was also assessed after measurement at 10 time points, no difference was 211 observed between p.S539W allele carriers and non-carriers (Table 1).

Levels of additional amidated hormones (Gastrin-amide, Gastrin-Gly and CCKamide) with relevance to glucose homeostasis were also assessed. There was no difference at baseline or at maximal stimulation in gastrin-gly, gastrin amide and CCK-amide levels between carriers and non-carriers (**Supplementary Figure 4** and **Table 1**).

To further delineate the mechanism of PAM deficiency on GLP-1 resistance, whole body and pancreas-specific mouse knockout models were studied. Induced whole

body Pam knockout (UBC-Cre Pam^{fl/fl} mice) resulted in greater postprandial 219 220 glycaemia during an OGTT than in wildtype control mice (Fig. 3c). Importantly, pancreas-specific knockout mice (PDX1-Cre Pam^{fl/fl}) did not have altered glycemia 221 222 following an OGTT, suggesting that Pam affects glycaemic control mostly through 223 extra-pancreatic tissues (Supplementary Fig. 5a). Gastric emptying rate (GE), the 224 predominant GLP-1 mechanism mediating postprandial glycaemic control, was measured by a paracetamol absorption test in UBC-Cre *Pam^{1//II}* mice^{26, 27}. Consistent 225 with GLP-1 resistance ubiquitous loss of Pam caused an increased GE rate in UBC-226 227 Cre *Pam^{fl/fl}* mice compared to control animals (**Fig. 3d**). Despite treatment with the 228 GLP-1 receptor agonist (Exendin 4), the GE rate of Pam knockout mice remained 229 faster than wildtype controls, also consistent with increased GLP-1 resistance in the 230 absence of Pam (Fig. 3e). The difference in GE between murine whole-body Pam 231 knockout and control was almost entirely abolished by treatment with GLP-1 receptor 232 antagonist Exendin-9 (Fig. 3f), demonstrating that GLP-1 action is the major 233 mediator of this difference in GE rate between whole-body Pam knockdown and control mice. To mechanistically explain the causes of GLP-1 resistance and 234 increased gastric emptying in UBC-Cre Pam^{fl/fl} mice, we analyzed the expression of 235 236 the GLP1 receptor (GLP1R) in the gastric pylorus, which influences GE rate, and in other tissues. UBC-Cre Pam^{fl/fl} mice had a 62% reduction in pyloric GLP-1R 237 expression compared to *Pam^{f1/f1}* littermates (p<0.0001) (**Fig. 3g**). Reduction in *GLP1R* 238 239 expression was not observed in the other tissues tested (islet, and kidney) (Fig. 3h-240 i), whilst expression of other gastric hormone receptors in the pylorus were 241 unchanged, with the exception of the GRP receptor. Circulating levels of GRP were 242 also increased in response to a glucose load (Supplementary Figure 5b-c).

243

244 **PAM LoF alleles carriers demonstrate resistance to treatment with GLP-1RA**

245 Evidence of GLP-1 resistance in the physiological setting prompted examination of 246 the therapeutic response to GLP-1RA. A meta-analysis of 1,119 patients treated with 247 GLP-1RAs in 3 investigator led cohorts (IMI-DIRECT, GODARTs and PRIBA) was 248 performed, where HbA1c was measured at initiation of GLP-1RA treatment and at 6 249 months. Individuals in these studies were treated with liraglutide, exenatide or 250 exenatide LAR. In non-carriers of the PAM LoF alleles the mean absolute HbA1c 251 change across the 3 studies after GLP-1 treatment was -1.24% (13.6 mmol/mol). 252 The meta-analysis demonstrated a significant reduction in HbA1c with 6 months of 253 therapy with GLP-1RA in both carriers and non-carriers of PAM LoF alleles (Fig. 4). 254 The absolute magnitude of this reduction was significantly less in heterozygous 255 carriers of the p.S539W PAM allele with a mean change in HbA1c of 0.69% (7.5 256 mmol/mol). This amounted to an absolute loss of 0.55% (6.0 mmol/mol) HbA1c 257 lowering per allele, p=0.025. A suggestive albeit non-significant difference in 258 absolute HbA1c lowering was observed in heterozygous carriers of p.D563G after 259 GLP-1RA initiation (-0.25% (2.7mmol/mol) per allele, p=0.050). The meta-analysis 260 demonstrated a clinically meaningful reduction in this response to GLP-1RA in both 261 carriers of the p.S539W or the p.D563G (Fig. 4). This represents a relative loss of 262 either 44% or 20% of the HbA1c lowering associated with GLP-1 RA use 263 respectively. Of note, in the DIRECT study, carriers of p.S539W had an 264 independently significant reduction in response to GLP-1RA (-0.67% (7.3mmol/mol) 265 per allele, p=0.034). In these studies, 11.5% of p.S539W carriers and 18.5% of 266 p.D563G carriers in whom GLP-1RA treatment was initiated achieved the 267 recommended HbA1c target of <7% compared to 25.3% of non-carriers.

To determine if a reduced response to GLP-1RA was driven by a GLP-1 specific effect we also determined the effect of *PAM* genotype on the response to three other commonly used anti-diabetic drugs, DPP-4i, metformin, and sulphonylureas, in the same studies. No significant differences were detected in response to any these medications between carriers and non-carriers of the *PAM* LoF alleles (**Supplementary Table 3-5** and **Supplementary Fig. 6**).

274 We then sought to reproduce this finding by examining the effect of PAM genotype 275 on response to albiglutide therapy in the GSK-Harmony trial. The GSK data was not 276 included in the meta-analysis due to considerable methodological differences (the 277 option to intensify GLP-1RA therapy in non-responders, measurement of effect over 278 8 months rather than 6 months and the relatively small glycemic effect seen with 279 albiglutide). Both carriers and non-carriers of PAM LoF alleles again demonstrated a 280 reduction in HbA1c at 8 months. The magnitude of the reduction was 0.63%, 281 approximately half that seen in the meta-analysis. There was no difference in 282 response to GLP-1RA between carriers and non-carriers of the PAM p.S539W 283 (0.28% (3.1 mmol/mol), SE:0.18, p=0.12) and p.D563G (-0.04% (0.4 mmol/mol), 284 SE:0.07, p=0.53) alleles. Given the inconsistent effect observed in the GSK-285 Harmony trial and the meta-analysis, which comprised of 3 different GLP-1RA, we 286 sought to assess agonist-specific effects. Retrospective analysis by agonist, 287 although underpowered, and comprising different study designs demonstrated a 288 reduced response to liraglutide in carriers of p.D563G but not p.S539W (p.D563G -289 0.25% (2.7 mmol/mol), p=0.05 & pS539W -0.16%, p=0.55). Response to exenatide 290 was reduced in carriers of p.S539W but not p.D563G (p.D563G -0.14% (1.5 291 mmol/mol), p=0.54 & pS539W -0.81% (8.9 mmol/mol), p=0.035). There was no 292 difference in response to albiglutide in either of the PAM T2D-risk allele carriers

(p.D563G -0.03% (0.3 mmol/mol), p=0.73 & pS539W 0.30% (3.3 mmol/mol),
p=0.15) (Supplementary Fig. 7). There was no significant effect of genotype on
weight change for either p.S539W (-0.06kg, 95%CI [-1.26,1.14]) or p.D563G (0.27kg,
95%CI [-0.29,0.82]) in the albiglutide treated Harmony study.

297 To further exclude an abnormal pancreatic response to GLP-1, we assessed the 298 response to GLP-1RA treatment *in vitro* in a human beta-cell model EndoC-βH1 to 299 determine the effect of PAM loss on insulin secretion. No difference between 300 baseline insulin secretory response and glucose and GLP-1 stimulated insulin 301 secretory response was demonstrated between control and PAM knockdown (Supplementary Fig.8a). Similarly, islets isolated from UBC-Cre Pam^{fl/fl} mice and 302 Pam^{fl/fl} littermates and treated with GLP-1 (both amide and glycine-extended) had 303 304 similar levels of insulin secretion (Supplementary Fig. 8b).

305 **DISCUSSION**

Translating genome wide association signals in T2D, into clinically useful information has been challenging. In this study we demonstrate how in-depth physiological characterization of a GWAS signal can lead to biological insight in T2D and subsequent focused examination of pharmacogenetic studies can provide implications for a currently available treatment. We demonstrated that two LoF alleles in PAM resulted in reduced PAM activity and caused GLP-1 resistance in the physiological and pharmacological setting.

313 Using tissue specific Pam knockout in mice allowed an assessment of where 314 resistance is occurring. The observation of significantly higher blood glucose 315 concentration in whole-body knockout but not in pancreas specific knockout upon 316 oral glucose delivery suggests the dominant effects of PAM T2D-risk alleles on 317 glycaemic regulation is occurring outside the pancreas. The demonstration of 318 reduced GLP-1R expression in the pylorus, a regulator of GE rate, and 319 demonstration of increased GE rate in mice regardless of GLP-1 abundance is highly 320 suggestive that this is the mechanism driving GLP-1 resistance. Supportive of this 321 mechanism was the reduction in difference in GE between whole body Pam 322 knockout mice and controls when both were treated with exendin-9 (a GLP-1 323 antagonist). It is important to note GE rate did not completely normalize and this may 324 suggest the contribution of another amidated peptide. Together these data support 325 the interpretation that GLP-1 levels were elevated in models of PAM deficiency due 326 to GLP-1 resistance.

Given that delay to adequate treatment has been shown to increase diabetic complications, this raises concern about the use of GLP-1 receptor agonists in carriers *PAM* LoF alleles⁵. Importantly, we demonstrate that there was no impact of

PAM genotype on response to metformin, sulphonylurea, or DPP-4i with the latter
 two medications considered alternate second line medication choices in individuals
 without heart disease or renal impairment.

As pharmacogenetic cohorts increase in size and more alleles are identified which predict treatment response, a likely development will be the development of polygenic risk scores which predict likely response of an individual to the various diabetes agents.

337 Conclusion

In conclusion, mechanistic examination of the T2D *PAM* locus revealed that carriers of LoF alleles have reduced serum enzyme activity and GLP-1 resistance. The GLP-1 resistance in these carriers resulted in a specific and clinically meaningful reduction in response to exenatide and liraglutide. Data from a *Pam* mouse knockout model suggests that the mechanism of GLP-1 resistance is linked to dysregulated GE. The use GLP-1RA will not be as efficacious at reducing HbA1c in carriers of *PAM*T2D risk alleles.

345 Acknowledgements

346 ALG is a Wellcome Trust Senior Fellow in Basic Biomedical Science. MIM was a 347 Wellcome Senior Investigator and NIHR Senior Investigator. ERP was a Wellcome 348 Trust New Investigator (102820/Z/13/Z).BH is supported by а 349 Diabetes UK RD Lawrence Fellowship 19/0005965. This work was funded by the 350 Wellcome Trust (095101 [ALG], 200837 [ALG], 098381 [MIM], 106130 [ALG, MIM], 351 203141 (ALG, MIM], 203141 [MIM]), Medical Research Council (MR/L020149/1) 352 [MIM, ALG, FK, ATH], European Union Horizon 2020 Programme (T2D Systems) 353 [ALG, TH], and NIH (U01-DK105535; U01-DK085545) [MIM, ALG] and UM-

354 1DK126185 [ALG], the National Institute for Health Research (NIHR) Oxford 355 Biomedical Research Centre (BRC) [ALG, MIM, FK]. The views expressed are those 356 of the author(s) and not necessarily those of the NHS, the NIHR or the Department 357 of Health. The study was supported by the Novo Nordisk Foundation (Grant 358 number NNF18CC0034900). The study was supported by a grant by Boehringer 359 Ingelheim (MS). The work leading to this publication has received support from the 360 Innovative Medicines Initiative Joint Undertaking under grant agreement n°115317 361 (DIRECT), resources of which are composed of financial contribution from the 362 European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA 363 companies' in-kind contribution. This publication is based on research using data 364 from GSK (HARMONY trials) that has been made available through secured access. 365 GSK has not contributed to or approved, and is not in any way responsible for, the contents 366 of this publication. We thank both GSK 367 and www.ClinicalStudyDataRequest.com for providing us data and access. The 368 ADDITION-PRO study was funded by an unrestricted grant from the European 369 Foundation for the Study of Diabetes/Pfzer for Research into Cardiovascular 370 Disease Risk Reduction in Patients with Diabetes (74550801), by the Danish Council 371 for Strategic Research and by internal research and equipment funds from Steno 372 Diabetes Center. This work was supported by the European Union's Horizon 2020 373 research and Innovation programme (Grant Agreement No 667191). AJ is supported 374 by the Danish Council for Independent Research, European Union, FP7, Marie Curie 375 Actions, IEF, Lundbeck Foundation (R140-2013-13313), Novo Nordisk Foundation 376 and Danish Diabetes Academy (NNF17SA0031406, PDMI002-18)

The PRIBA study was funded by A National Institute for Health and Care Research
(U.K.) Doctoral Research Fellowship (DRF-2010-03-72, Jones) and supported by the

- 379 National Institute for Health Research and Care Clinical Research Network. The
- 380 views expressed are those of the author(s) and not necessarily those of the NIHR or
- the Department of Health and Social Care.

382 Conflicts

- 383 ERP has received honoraria from Lilly, Sanofi and Illumina. MIM holds stock options
- in Roche. ALG's spouse is an employee of Genentech and holds stock options in
- 385 Roche.

386 **Online Methods**:

387 Methods

388 Human Subjects

All volunteers provided written informed consent. The protocol was approved by
 Oxford B NRES Research Ethics Committee. The study was registered prospectively
 (ClinicalTrials.gov:NCT02723110).

Human Biochemical and Clinical methods

393 To establish the impact of T2D associated LoF alleles (p. D536G & p.S539W) on 394 PAM enzyme activity in carriers, stored serum samples from the Oxford Biobank 395 (OBB) and a prospective collected serum from a recruit-by-genotype study were 396 analyzed¹⁷. PAM activity was measured using a previously described radiotracer 397 method (supplementary section 1.1) in 24 heterozygous carriers of p.S539W, 27 398 heterozygous carriers of p.D563G and 21 homozygous carriers of p.D563G and age, sex and BMI matched non-carriers^{28, 29}. All individuals were normoglycaemic and of 399 400 white European background and measurements were performed in triplicate.

Plasma glucose was measured using the ilab 650 Analyser (Instrumentation Laboratory Ltd, Warrington, UK) as previously described¹⁷. Serum insulin concentrations were measured using the Human Specific Insulin RIA Kit (EMD Milipore, Billerica, USA)¹⁷. Radioimmunological determinations of intact, amidated and glycine extended plasma GLP-1 concentration were performed as described previously³⁰. Gastrin and CCK were measured using non-commercial antibodybased assays as previously described ^{11, 31}.

408 Retrospective analysis of intact GLP-1 (7-36 amide and 9-36 amide) profiles 409 following a 75g OGTT was performed in two Danish cohort studies (AdditionPro and

Family Study)^{19, 20.} Normoglycaemic carriers of the T2D -risk alleles p.S539W and p.D563G were matched for age, BMI and sex to two non-carriers. Demographics of the 2 studies are provided in table S1 (**Supplemental section 2.1**). Individuals with T2D were excluded prior to analysis to minimize effects associated with treatment and avoid reduction in incretin effect observed in overt hyperglycaemia^{32.}

415 Twenty carriers of the low frequency PAM p.S539W T2D-risk LoF allele and twenty 416 matched non-carriers were prospectively recruited to into a double blind, 417 observational, recruit-by-genotype study to corroborate findings of the retrospective 418 analysis and to assess the impact of *PAM* genotype on plasma GLP-1 levels and the 419 incretin response. Genotype was reconfirmed on day 1 of the study (table 1). One 420 pair was excluded due to genotyping error. Subjects were recruited from the OBB 421 and all were of white European background and normoglycaemic. Subjects 422 underwent a 4 hour frequently sampled OGTT and matched isoglycaemic clamp (the 423 gold standard assessment of the incretin effect) (Supplemental information, section 4.1) on separate study days²⁵. Blood samples were collected at 10 time 424 425 points for biochemical analysis and blood glucose was measured in real-time every 5 426 min to facilitate the isoglycaemic clamp. The effect of genotype on the various 427 outcomes was assessed using a 2-sided t-test, RM-ANOVA or mixed effect analysis 428 as appropriate. All data are displayed as mean \pm SD.

The study utilized an adaptive study design with an interim analysis at 40 volunteers (20 v 20) with the possibility of adding an additional 20 volunteers to the study (10 v 10) if the criteria for futility or clear effect are not met. The criteria were; stop and reject null hypothesis if t > 2.490 and stop and accept null hypothesis if t < 1.033. If the t fell between these values an additional 20 volunteers (10 v10) were to be recruited. The decision to stop or include additional volunteers was be based on the

incretin effect (primary outcome) and prospectively listed on the clinicaltrials.govregistry.

This provided a 90% chance of detecting a difference of 10% with an alpha 5%
(estimated SD of 10%) in incretin effect at the first stopping point.

439 *Pharmacogenetics*

440 Response to GLP-1RA and other oral hypoglycemic agents (DPP-4i, metformin and 441 sulphonylurea) were compared between carriers and non-carriers of PAM p.S539W 442 and p.D563G carriers. Response to GLP-1RA was initially assessed by comparing 443 the response to treatment of 1,119 patients with T2D treated with GLP-1RA in a 444 meta-analysis of the three similar cohorts (GODARTS, IMI-DIRECT and PRIBA) and 445 replication was sought in the methodologically different GSK-Harmony Trial 446 (N=1,292, predominantly albiglutide). Cohort demographics and study design are 447 provided in supplemental information (section 3.1). In the discovery meta-analysis, 448 response was determined in all 3 studies by HbA1c change from baseline (day of 449 initiation of medication) to the HbA1c at 6 months of therapy. The clinical model for 450 assessing treatment response was developed using linear regression and backward 451 elimination through the stepAIC function in the MASS package in R³³. A linear 452 regression was performed adjusting for clinical covariates: baseline HbA1c, age at 453 diagnosis, duration of diabetes, number of oral glycemic agents (OHA) at initiation of GLP-1RA, insulin dose and change in OHA. A meta-analysis was performed using a 454 fixed effects model in the Forrest package of R³⁴. In the GSK-Harmony trial data the 455 456 effect of genotype on HbA1c was determined using a similar model. The method 457 differed due to differences in study design which include that the HbA1c was 458 measured at baseline and at 8 months to determine the change in HbA1c. 459 Significantly, in the GSK-Harmony studies there was the opportunity for dose 460 increase at 5 weeks if it was felt that participants were not responding. The study 461 was conducted over multiple sites so in addition to the model used in the discovery 462 meta-analysis study "site" was included as a factor in the clinical model. Finally, to 463 examine agonist specific effects, data from all 4 studies were pooled in "a by-agonist 464 meta-analysis" (Figure 5). The effect of PAM genotype on metformin and 465 sulphonylurea response was also assessed in GoDARTs and IMI-DIRECT and used 466 the same model as the assessment of GLP-1 in these cohorts. Details of cohorts 467 for these analyses are provided in supplemental information (Section 3.1).

468 Insulin secretion in the human EndoC- β H1 cell line

469 EndoC- β H1 cells were cultured, platted in a 96-well plate and transfected with siRNA as described previously^{7, 35} or incubated for 48 h with either DMSO or 500µM 4-470 471 Phenyl-3-butenoic acid (PBA, Sigma #155322). Platted cells were incubated the 472 night prior to the experiment in culture medium with 2.8 mM glucose. On the day of 473 the assay, cells were incubated in glucose-free culture medium for 1hr and then 474 stimulated with either 1 mM or 10 mM glucose. The latter stimulation was 475 complemented with either GLP-1 (7-36) amide (1 nM, BACHEM #4030663), 476 tolbutamide (200 μM, Fluka Analytical #T0891), or Forskolin (10 μM, Merck #F3917). 477 Residual cells were removed by centrifuging the collected supernatants (4°C, 700g, 478 5min) and 50µL of the supernatant was stored at -20°C until the assay. Samples to 479 measure insulin content were harvested in 100µL of acid ethanol (1.5% conc. HCl, 480 75% ethanol, and 23.5% distilled H_2O) in the 96-well plate and stored at -20°C. 481 Insulin concentrations of both supernatants and cellular contents were determined 482 using Insulin (human) AlphaLISA Detection Kit (PerkinElmer). Data presented are 483 the result of 3 biologically independent experiments on two different passages of 484 EndoC- β H1 lines. Each biological replicate is the average of 3 technical replicates.

We used a 2-way ANOVA followed by a Tukey post hoc test to evaluate the interaction between the transfection (siControl vs. siPAM) or treatment (DMSO vs. PBA), and the various stimulations of insulin secretion detailed above. (add sequences of siControl vs. siPAM)

489 *Generation & Characterisation of Pam* knockout mouse models

490 All animals were housed in a pathogen-free animal facility at the Institute of 491 Molecular Health Sciences at ETH Zürich. Mice were maintained in a temperature-492 and humidity-controlled room on a 12 h light/ dark cycle (lights on from 6:00 to 493 18:00). Mice were given ad libitum access to a standard laboratory chow and water. 494 All animals were at least 8 weeks of age. Experiments were performed 495 independently in both sexes, and figures display representative experiments. Pam^{1//I} 496 mice were generated in the ETHZ EPIC facility by injecting blastocysts with Pam-497 targeted ES cells obtained from EUMMCR (clone EPD0607 1 A11). Founders 498 (tm1a - Pamfineo/fineo) were screened for the presence of the targeted allele and 499 neo cassette, and bred with FLP-Deleter (B6.129S4-Gt(ROSA)26Sortm1(FLP1) Dym/RainJ) to remove the neo cassette (to obtain tm1c – Pam^{fl/fl} allele) 500 (Supplementary Fig. 1A). UBC-Cre mice (Tg[UBC-cre/ERT2]1Eib - purchased from 501 Jackson Laboratories) were crossed with Pam^{11/fl} to obtain UBC-Cre PAM^{11/fl}. To 502 create PDX1-Cre Pam^{fl/fl} mice, B6.FVB-Tg(Pdx1-cre)6Tuv/J were crossed with 503 Pam^{fl/fl} and backcrossed. All animal experiments were in accordance with 504 505 institutional guidelines and approved by the kantonale Veterinäramt Zürich.

506 Tamoxifen injection for Cre-mediated Pam^{fl/fl} allele recombination

507 Mice at 4 weeks of age were administered daily intraperitoneal injections of 2 mg 508 tamoxifen (T5648, Sigma) for 5 days, dissolved at a concentration of 20 mg/mL in 509 10% Ethanol/90% corn oil.

510 Oral Glucose Tolerance Test

511 Mice were fasted for 6 h and D-glucose (Sigma, 49139) solution (2 g/kg) 512 administered by gavage. Blood glucose values were measured by tail nick with a 513 Bayer Contour XT glucometer at 0, 15, 30, 45, 60, and 120 min after injection.

514 GLP-1 measurement

515 Mice were injected intraperitoneally with dipeptidyl peptidase-4 (DPP-4) inhibitor 516 Sitagliptin (Merck, $3 \mod/kg$) at $t \equiv 0$ and after $30 \min$, D-glucose (Sigma Aldrich 517 $2 \boxdot/kg$) was administered orally by gavage. Blood was sampled $5 \liminf$ thereafter 518 and added to $5 \square \mu$ l Aprotinin (Sigma, $5 \mod/m$ l), $2 \square \mu$ l EDTA (0.5 \square M) and, $3 \square \mu$ l 519 DPP-4 Inhibitor (Millipore) on ice. Blood was collected from the tail vein, serum 520 isolated and GLP-1 content was measured with GLP-1 ELISA (Merck).

521 Paracetamol gastric emptying assays

522 10 mg/mL of paracetamol (Acetaminophen, Panadol) and 0.2 g/mL glucose in PBS 523 were administered by gavage (at a final dose of 0.1 mg/g and 2 mg/g of body 524 weight). Blood was collected from tail vein before gavage, at 15, 30, 45 and 60 525 minutes after gavage, and concomitantly blood glucose was measured with a Bayer 526 Contour XT glucometer. Serum was used to measure paracetamol at each time point 527 (Paracetamol Test Kit Triple Enzyme, K8003, CLS diagnostics, UK).

528 In experiments using Exendin 9 (Exendin 9-39, Biozol MBS826292-5), the 529 compound was injected intraperitoneally 5 min prior to gavage at dose of 50 530 µg/mouse.

- 531 In assays including Exendin 4 (Exenatide, Bydureon, AstraZeneca), the compound
- 532 was injected intraperitoneally 30 min prior gavage at the concentrations of 10
- 533 nmol/kg.

535 GLP-1-stimulated insulin secretion in mouse pancreatic islets

Mouse pancreatic islets were isolated from adult Pam^{1/fl} and UBC-Cre Pam^{1/fl} 536 537 littermates. After sacrifice, a total of 2 ml of Liberase (5 mg/ml) (Sigma 538 05401127001, diluted in HBSS buffer, GIBCO, 14170-112) was injected through the 539 common bile duct to perfuse the whole pancreas. The perfused pancreas was 540 dissected and incubated at 37°C for 17 min. Digested exocrine cells and intact islets 541 were separated via centrifugation (2400 rpm for 20 min with very slow acceleration 542 and no braking) over Histopaque-1077 (Sigma, 10771), and intact islets were 543 manually picked under the microscope. Islets from each mouse were kept separated 544 and were cultured in RPMI 1640 with 10% FBS and 100 U/ml penicillin/streptomycin 545 overnight, while genotype was reconfirmed by PCR.

546 The next day, islets were picked and equilibrated in Dulbecco islet secretion media + 547 0.2% BSA with 1 mM glucose for 30 min in p24-well plates, then transferred to 548 experimental conditions for 1 h. Each experimental condition (250 µL of Dulbecco 549 islet secretion media with 1 mM glucose, or with 10 mM glucose, or with 10 mM 550 glucose + 1 nM GLP-1 (7-36amide, product n. 4030663, Bachem Switzerland) or 551 with 10 mM glucose + 1 nM GLP-1 (7-37 glycine extended, product n. 4034865, 552 Bachem Switzerland) had exactly 5 equally sized islets and was tested in three 553 technical replicate per mouse. At the end of the secretion assay, islets were 554 collected and disrupted in acid/ethanol solution (95% v/v absolute ethanol, 5% v/v 555 acetic acid and 0.1% v/v Triton X-100), sonicated briefly, spun down and supernatant 556 diluted 1:500 to measure insulin content with an insulin ELISA (Elpco), while 557 supernatant was spun down to remove shed cells, and insulin concentration 558 measured. Insulin secretion is expressed as the ratio between total secreted insulin

and total islet insulin. Islets not used for secretion assays were briefly washed andplaced in Trizol for RNA quantification.

561 RNA isolation and quantification

562 TRIzol reagent (Invitrogen, 15596-026) was used for RNA isolation according to the 563 manufacturer's protocol. RNA was reverse transcribed using High Capacity cDNA 564 Reverse Transcription Kit (Applied Biosystems, 4368813). Quantitative PCR was 565 performed in an LC480 II Lightcycler (Roche) and using gene specific primers and 566 Sybr Fast 2x Universal Master mix (Kapa biosystems, KK4611). Results were 567 normalized to 36b4 mRNA levels.

568 HPLC-based YVG amidation assay


569 Custom made Dansyl-YVG peptide, and control amidated product Dansyl-YV-amide, 570 was synthesized by JPT peptide technologies GmbH. The amidation assay method 571 is a slight adaptation of the method described by Eipper and colleagues (Czyzyk et 572 al., 2005; Kolhekar et al., 1997; Ul-Hasan et al., 2013). Tissues were flash frozen, 573 then amidation buffer added (NaTES pH7 20 mM, Mannitol 10 mM, Triton X-100 1% 574 v/v freshly open at each lysis buffer preparation) additioned with fresh 1 mM 575 pepstatin, 1 mM PMSF, 1 mM soya beans trypsin inhibitor (all from Sigma). Samples 576 were homogenized for 2 min at 30Hz with TissueLyser II (Qiagen), then underwent 577 three freeze-thaw cycles before removing debris with centrifugation at 2000 rpm for 578 15 min at 4°C, and supernatant quantified and stored frozen. 50 mg of tissue lysate 579 was added to obtain a total of 50 µL of the amidation assay buffer composed of: 580 Catalase 100 ug/mL (freshly prepared), 2 mM L-ascorbic acid (freshly prepared), 581 ZnCl₂ 2 μM, CaCl₂ 2 μM, CuSO₄ 75 μM, NAMES 100 mM, pH 5.5, 0.15 mM Dansyl-582 YVG. All chemicals were from Sigma. The reaction was then incubated for 2, 4 or 6 h 583 in a 37°C water bath before being collected and spun down in Amicon® Ultra 0.5 mL

584 filter vial (Merck Millipore). The flow through was then measured via 585 chromatographic analysis of chemically converted Dansyl-YVG into Dansyl-YV-NH2 586 or Dansyl-YVG(OH) YVG substrate into the Dansyl-YV- hydroxyglycine intermediate 587 and the amidation product dansyl-YV-N2 by means of high-performance liquid 588 chromatography (HPLC) as described by UI-Hasan and colleagues (REF PMID: 589 23994590). The absorbance of substrate, intermediate and product were detected at 590 220 and 280 nm on a C18 analytical column over a linear gradient ranging from 22% 591 to 25% of solvent (acetonitrile) in 20 min.

592

593 Data Availability

All other data generated or analysed during this study are included in this published article (and its supplementary information files). IMI-DIRECT data access is available on request (DIRECTdataaccess@dundee.ac.uk). HARMONY data can be requested via clinicalstudydatarequest.com. De-identified participant-level data generated in this study from the Oxford Biobank can be requested from the corresponding author pending approval from the Oxford Biobank.



603

604


607

605 Figure 1. Amidation activity in *PAM* missense allele carriers and in *Pam* knockout 606 mice.

608 **A:** Panel A demonstrates the reduction in serum enzyme activity in heterozygous carriers of 609 p.S539W (N=19) compared to age, sex and BMI matched non-carriers (N=19) (left). All 610 samples were measured in triplicate and the data points presented above are the mean of 611 the triplicates. Dashed lines connect the BMI, age and gender matched non-carrier to the 612 corresponding carrier.

B: Panel B demonstrates the reduction observed in heterozygous (N=27) and homozygous carriers (N=21) of p.D563G compared to age, sex and BMI matched non-carriers respectively. Data have been normalised to non-carriers to allow comparison between genotypes. Carriers were 1:1 matched for age, gender, and sex. All samples were measured in triplicate and the data points presented above are the mean of the triplicates. The long black line represents the mean amidating activity +/- the SEM.

C: Panel C demonstrates the percentage of PAM-mediated conversion of Dansyl-YVG-COOH intermediate and Dansyl-YV-NH₂ product from Dansyl-YVG in an amidation assay in pituitary extracts UBC-Cre $Pam^{fl/fl}$ mice or $Pam^{fl/fl}$ (N=2,2) after 2 hours from the start of the assay. The error bar represents SD.




624

Figure 2. GLP-1 profiles of carriers of PAM loss-of-function alleles

A-B: Panel A & B demonstrate the amidated GLP-1 profile of carriers of p.D536G (A) and p.S539W (B) and age gender and BMI matched non-carriers following a 75g OGTT in the Family Study. Each data point is the mean amidated GLP-1 concentration ± SD. Panel A demonstrated the amidated GLP-1 profiles of 24 carriers of p.D536G and 48 matched noncarriers. Panel B demonstrates the amidated GLP-1 profiles of 3 carriers of p.S539W and 6 non-carriers.

C: Panel C demonstrates the total GLP-1 (sum of amidated and non-amidated GLP-1) plasma profiles of 19 heterozygous carriers of S539W and 19 age, gender and BMI matched non-carriers in the prospectively performed 75g OGTT. Each data point is the total GLP-1 concentration \pm SD. Analysis was performed using RM-ANOVA. Note: total GLP-1 is displayed as amidated and non-amidated GLP-1 was measured but there was no difference in the ratio between amidated and non-amidated GLP-1 at any time point and both forms of GLP-1 have equal biological activity³⁶.

- 639 D: Amidated GLP-1 concentration pre- and 30 min after re-feeding in UBC-Cre Pam^{fl/fl} mice
 640 or Pam^{fl/fl} littermates (N=5,5). Error bar represents SD. Analysis was via non-paired T-test.
- 641



647 Figure 3. PAM loss leads to GLP-1 Resistance

648 **A:** Panel A demonstrates the incretin effect in 19 heterozygous carriers of p.S539W and 19 649 matched non-carriers as measured by the IV glucose required as a percentage of 75g to re-650 produce a glucose curve associated with a 75g oral glucose load. Error bars represent SD.

651 **B:** Panel B demonstrates the ratio between peak GLP-1 concentration and incretin effect in

B. Partiel B demonstrates the ratio between peak GLP-1 concentration and increan enect in
 19 heterozygous carriers of p.S539W and 19 matched non-carriers. This is a surrogate of
 GLP-1 sensitivity and demonstrate a significant reduction in GLP-1 sensitivity in carriers of

654 S539W compared to non-carriers. Error bars represent SD.

C: Panel C demonstrates the blood glucose concentration after glucose load in UBC-Cre *Pam^{fVfI}* mice or *Pam^{fVfI}* littermates (N=7,7). Induced whole body Pam knockout (UBC-Cre *Pam^{fVfI}* mice) resulted in greater postprandial glycaemia during an OGTT than in wildtype 658 control mice. Error bar indicates SD.

D: Plasma paracetamol concentration after oral paracetamol load which is a surrogate for gastric emptying rate. The higher concentrations of paracetamol concentration observed in Pam knockdown are consistent with more rapid paracetamol absorption and faster gastric emptying. This figure demonstrates significantly higher paracetamol concentration in the induced whole body Pam knockout (UBC-Cre *Pam^{fl/fl}* mice) (N=7,7). Error bar indicates SD.


E-F: Panel E demonstrates the effect of whole body Pam knockout on gastric emptying during treatment with GLP-1 receptor agonist (exendin-4) as measured by the paracetamol absorbtion test (N=4,8). Paracetamol concentration is significantly higher in whole body Pam knockout compared to control. Figure F demonstrates the gastric emptying rate in during treatment with GLP-1 receptor antagonist (exendin-9) (N=4,8). Error bar indicates SD.

669 **G-I**: Figures G-I demonstrate reduced expression of the GLP-1 receptor in the pylorus of the 670 stomach in whole body Pam knockdown (G) (N=5,5), and no change in expression in 671 pancreatic islets (H) (N=2,2) or kidney (I) (N=3,3). Error bar indicates SD.

672

673

674



676

677 Figure 4. Meta-analysis of the effect of carrying LoF alleles at p.D536G and

678 p.S539W on response to GLP-1RA therapy

679 The effect of carrying p.D536G and p.S539W on treatment response to GLP-1RA. Each 680 study is displayed separately, and the effect size is indicated by the location of a solid box 681 with the 95% CI displayed either side. The line of no effect is indicated by a vertical dotted line. The summary estimate of the effect of each allele is displayed below the individual 682 683 cohort summaries and is indicated by a solid black diamond with the center of the diamond 684 indicating the summary estimate and the lateral points the 95% CI. The effect is displayed is 685 the mean absolute HbA1c change between baseline and 6 months (% DCCT units). The 686 meta-analysis comprises 1,119 individuals across the 3 studies 130 carrier p.D563G and 26 687 carriers of pS539W.

689	Table 1: Clinical & biochemical characteristics of genotype-based recall study	/
-----	--	---

690

	Non-carrier	p.S539W carrier	P Value
Age (years)	50.9 ± 5.8	50.6 ± 5.9	0.23
Sex (m/f)	13/6	13/6	1.0
BMI (kg/m2)	24.9 ± 3.3	24.4 ± 3.1	0.18
Waist : hip ratio	0.86 ± 0.1	0.87 ± 0.09	0.83
Glucose AUC (mmol.I-1.min-1)	1560 ± 226	1652 ± 301	0.23
Insulin AUC	8422 ± 3582	11530 ± 7769	0.09
Total GLP-1 auc (min.pmol/l)	6887 ± 230	7692 ± 304	0.04
Incretin effect (%)	50.7 ± 11.2	47.5 ± 14.4	0.50
Gastrin amide fold change	1.63 ± 0.43	1.47 ± 0.48	0.09
Gastrin gly fold change	1.06 ± 0.18	1.04 ± 0.49	0.71
CCK amide	3.12 ± 4.72	3.58 ± 4.34	0.78
TSH	1.54 ± 0.49	1.34 ± 0.53	0.26
GIP auc (min.pmol/l)	11781 ± 4725	11670 ± 5518	0.95

691

692 Data are presented as the mean ± SD. Fold change for gastrin was calculated as the ratio

between t_0 and t_{30} . Fold change for CCK amide was calculated at t_0 and t_{60} .

695 **References:**

1 IDF. International Diabetes Federation. IDF Diabetes, 7 ed. Brussels,

697 Belgium: International Diabetes Federation, 2015. <u>http://www.diabetesatlas.org</u>.
698 2015.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et *al.* Management of hyperglycemia in type 2 diabetes: a patient-centered approach:
position statement of the American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD). *Diabetes Care.* 2012; **35**: 1364-79.

Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The
 prevalence of meeting A1C, blood pressure, and LDL goals among people with
 diabetes, 1988-2010. *Diabetes Care*. 2013; **36**: 2271-9.

Dawed AY, Zhou K, Pearson ER. Pharmacogenetics in type 2 diabetes:
 influence on response to oral hypoglycemic agents. *Pharmacogenomics and personalized medicine*. 2016; **9**: 17-29.

Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al.
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet.* 2010; **42**: 579-89.

Huyghe JR, Jackson AU, Fogarty MP, Buchkovich ML, Stancakova A,
Stringham HM, *et al.* Exome array analysis identifies new loci and low-frequency
variants influencing insulin processing and secretion. *Nature genetics*. 2013; 45:
197-201.

716 7 Thomsen SK, Raimondo A, Hastoy B, Sengupta S, Dai XQ, Bautista A, et al.
717 Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic
718 beta-cells. *Nat Genet.* 2018; **50**: 1122-31.

Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper
monooxygenases and peptide amidation: structure, mechanism and function. *Cell Mol Life Sci.* 2000; **57**: 1236-59.

Eipper BA, Stoffers DA, Mains RE. The biosynthesis of neuropeptides:
peptide alpha-amidation. *Annual review of neuroscience*. 1992; **15**: 57-85.

10 Czyzyk TA, Ning Y, Hsu M-S, Peng B, Mains RE, Eipper BA, *et al.* Deletion of peptide amidation enzymatic activity leads to edema and embryonic lethality in the mouse. *Developmental Biology*. 2005; **287**: 301-13.

11 Rehfeld JF, Stadil F. The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. *J Clin Invest.* 1973; **52**: 1415-26.

Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N.
Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in
Eating and Glycemia in Health, Obesity, and After RYGB. *Physiological reviews*.
2017; **97**: 411-63.

Mains RE, Alam MR, Johnson RC, Darlington DN, Back N, Hand TA, *et al.* Kalirin, a multifunctional PAM COOH-terminal domain interactor protein, affects

cytoskeletal organization and ACTH secretion from AtT-20 cells. *J Biol Chem.* 1999;
274: 2929-37.

Roberge JN, Gronau KA, Brubaker PL. Gastrin-releasing peptide is a novel
 mediator of proximal nutrient-induced proglucagon-derived peptide secretion from
 the distal gut. *Endocrinology*. 1996; **137**: 2383-8.

15 Persson K, Gingerich RL, Nayak S, Wada K, Wada E, Ahrén B. Reduced

GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP

- receptor-deleted mice. American journal of physiology Endocrinology and
- 743 *metabolism*. 2000; **279**: E956-62.

744 16 Sayegh AI. The role of bombesin and bombesin-related peptides in the short-745 term control of food intake. Prog Mol Biol Transl Sci. 2013; 114: 343-70. 746 17 Karpe F, Vasan SK, Humphreys SM, Miller J, Cheeseman J, Dennis AL, et al. 747 Cohort Profile: The Oxford Biobank. Int J Epidemiol. 2018; 47: 21-21g. 748 Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, et 18 749 al. Deletion of the developmentally essential gene ATR in adult mice leads to age-750 related phenotypes and stem cell loss. Cell Stem Cell. 2007; 1: 113-26. 751 19 Gjesing AP, Ekstrom CT, Eiberg H, Urhammer SA, Holst JJ, Pedersen O, et 752 al. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic 753 polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits. 754 Diabetologia. 2012; 55: 1338-45. 755 20 Johansen NB, Hansen AL, Jensen TM, Philipsen A, Rasmussen SS, 756 Jorgensen ME, et al. Protocol for ADDITION-PRO: a longitudinal cohort study of the 757 cardiovascular experience of individuals at high risk for diabetes recruited from 758 Danish primary care. BMC Public Health. 2012; 12: 1078. 759 21 Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al. 760 GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 761 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. 762 Diabetes. 2015; 64: 2513-25. Legakis IN, Tzioras C, Phenekos C. Decreased Glucagon-Like Peptide 1 763 22 764 Fasting Levels in Type 2 Diabetes. *Diabetes Care*. 2003; **26**: 252-52. 765 Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial 23 766 concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic 767 patients. Diabetes. 2001; 50: 609-13. 768 24 Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in 769 type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29: 46-52. 770 25 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous 771 glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967; 46: 1954-62. 772 26 Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the 773 deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its 774 insulinotropic effect in healthy subjects. *Diabetes*. 2005; 54: 2212-8. 775 27 Umapathysivam MM, Lee MY, Jones KL, Annink CE, Cousins CE, Trahair LG, 776 et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-777 like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014; 63: 785-778 90. 779 28 Mizuno K, Sakata J, Kojima M, Kangawa K, Matsuo H. Peptide C-terminal 780 alpha-amidating enzyme purified to homogeneity from Xenopus laevis skin. Biochem 781 Biophys Res Commun. 1986; **137**: 984-91. 782 29 Kolhekar AS, Mains RE, Eipper BA. Peptidylglycine alpha-amidating 783 monooxygenase: an ascorbate-requiring enzyme. *Methods in enzymology*. 1997; 784 **279**: 35-43. 785 30 Orskov C. Rabenhoi L. Wettergren A. Kofod H. Holst JJ. Tissue and plasma 786 concentrations of amidated and glycine-extended glucagon-like peptide I in humans. 787 Diabetes. 1994; 43: 535-9. 788 Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clinical 31 789 *chemistry*. 1998; **44**: 991-1001. 790 32 Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, 791 Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-

792 1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86: 3717-23.

Ripley WNVaBD. Modern Applied Statistics with S. Fourth edn: Springer}2002.

795 34 Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. 796 2010. 2010; **36**: 48.

797 35 Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M,

798 Czernichow P, et al. A genetically engineered human pancreatic beta cell line

exhibiting glucose-inducible insulin secretion. *J Clin Invest.* 2011; **121**: 3589-97.

800 36 Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of

glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy

subjects are indistinguishable. *Diabetes*. 1993; **42**: 658-61.